Skip Navigation LinksHome > August 2014 - Volume 36 - Issue 6 > Pathologic Risk-based Adjuvant Chemotherapy for Unilateral R...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0000000000000141
Online Articles: Original Articles

Pathologic Risk-based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation

Sullivan, Erin M. MD*; Wilson, Matthew W. MD†,‡,§; Billups, Catherine A. MS; Wu, Jianrong PhD; Merchant, Thomas E. DO, PhD; Brennan, Rachel C. MD*,§,#; Haik, Barrett G. MD‡,§; Shulkin, Barry MD; Free, Tammy M. CCRP**; Given, Vickie CRA-RN**; Rodriguez-Galindo, Carlos MD*,#; Qaddoumi, Ibrahim MD, MS*,#

Collapse Box

Abstract

Background:

There are no standardized diagnostic or treatment guidelines for patients with advanced unilateral retinoblastoma.

Materials and Methods:

Patients with advanced unilateral retinoblastoma were prospectively treated after enucleation using a risk-based protocol. Patients were assigned to low risk (LR), intermediate risk (IR), or high risk (HR) based on pathology. LR patients underwent observation. IR patients received 4 courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC). In the HR group, patients received 3 courses of VDC alternating with 3 courses of vincristine, carboplatin, and etoposide (VCE) and irradiation when indicated.

Results:

Fifty patients with advanced unilateral retinoblastoma were treated (LR, n=36; IR, n=7; HR, n=7). All eyes were Reese-Ellsworth group V. All bone scans (n=81), lumbar punctures (n=16), and bone marrow aspirates (n=16) were negative. Chemotherapy was well tolerated. Grades 3/4 hematologic toxicities were seen in all patients; grades 3/4 nonhematologic toxicities were seen in half the patients. Only one patient in the HR group received radiation therapy. All patients were alive at the time of analysis with no signs of disease recurrence. Median follow-up was 3.4 years (range, 0.8 to 6.4 y).

Conclusions:

Patients with nonmetastatic unilateral retinoblastoma undergoing primary enucleation can be cured with a graduated intensity approach based on pathology.

Copyright © 2014 by Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.